



## IBEX Policy on Collaborative Research

---

IBEX is happy to collaborate with the research community in areas with genuine scientific interest which also coincide with IBEX commercial interests and budget.

There are in general three categories of studies:

1. Category I, a researcher initiated study, where a qualified researcher intends to use IBEX products as part of a study where none of the funding, other than contribution in kind (CIK), comes from IBEX.
2. Category II, a researcher initiated study which involves partial financial support (\$) from IBEX in addition to CIK.
3. Category III, a collaborative study (i.e. not fee-for-service), solely funded by IBEX where the Institution charges IBEX for services provided by the Institution.

Conditions Precedent:

1. The institution must be a bona-fide teaching and research institute granting degrees at the PhD level.
2. The study design must be of a quality acceptable for publication in a major journal.
3. The authors must be prepared to submit to IBEX (under terms of confidentiality) the results of the study 30 days prior to publication.
4. In the case of Categories II and III, the Institution's indirect upcharge must not exceed 15% of the direct costs.

Procedure:

1. The researcher should submit a brief non-confidential outline of the research proposal to IBEX ([collaborate@ibex.ca](mailto:collaborate@ibex.ca))
2. If the study objectives fit within IBEX's scope, IBEX and the Institution will enter into a Non-Disclosure Agreement and the researcher will provide IBEX with a detailed outline of the study plan.
3. After internal review, IBEX will respond to the researcher regarding the nature of the support IBEX will be able to give and any conditions that may apply.

August 1, 2010

---

IBEX Pharmaceuticals Inc.

5485 Paré, Suite 100, Montréal, Québec, Canada H4P 1P7  
Tél : (514) 344-4004 Fax : (514) 344-8827 Website : [www.IBEX.ca](http://www.IBEX.ca)